Founded in Tampa, Florida, Oragenics Inc. is a biotech company dedicated to developing innovative bacterial-based therapies. The company's core mission is to address unmet medical needs through cutting-edge research and development. Oragenics focuses on creating antibiotics for infectious diseases and has expanded its portfolio to include NT-CoV2-1, an intranasal vaccine candidate for COVID-19. Additionally, the company is working on LPT3-04, a weight loss candidate, and SMaRT Replacement Therapy, a topical treatment aimed at preventing dental caries.
Oragenics has garnered attention from notable investors and industry experts, contributing to its growing reputation in the biotech field. The company has achieved significant milestones, including advancing its vaccine candidate for COVID-19 and securing funding for its various research initiatives. Through its innovative approach and commitment to addressing critical health issues, Oragenics has made a substantial impact on the medical community, particularly in the areas of infectious disease and dental health.
